Cowen assumed coverage on shares of Prevail Therapeutics (NASDAQ:PRVL) in a research note released on Monday, AnalystRatings.com reports. The brokerage issued an outperform rating on the stock.
Shares of PRVL stock opened at $12.10 on Monday. Prevail Therapeutics has a 52-week low of $9.83 and a 52-week high of $16.90.
In other Prevail Therapeutics news, Director Carl L. Gordon purchased 882,352 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average cost of $17.00 per share, with a total value of $14,999,984.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.
Further Reading: How much money do you need to begin day trading?
Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.